18 February 2020 | News
Entered into a strategic partnership with a global vaccine leader
WuXi Vaccines, a new vaccine Contract Development and Manufacturing Organization (CDMO) established between WuXi Biologics and Shanghai Hile Bio-technology announced that it has entered into a strategic partnership with a global vaccine leader and signed a 20-year vaccine manufacturing contract valued approximately $3 billion USD, pursuant to which WuXi Vaccines will build a dedicated facility and supply a commercial vaccine products for the global market.
The business model of WuXi Vaccines is to build world-class integrated platforms and CDMO model to enable global companies to develop and manufacture vaccines.
As per the contract signed, WuXi Vaccines will build an integrated vaccine manufacturing facility including drug substance manufacturing (DS), drug product manufacturing (DP), Manufacture Science and Technology Labs (MS&T) as well as Quality Control labs (QC). The facility will be dedicated to manufacture one of its partner's vaccine products for the global market. The new facility is expected to be operational in 2022.
In Nov 2019, WuXi Vaccines announced 240 million USD investment to build the new vaccine manufacturing facility in Ireland. The facility is located within the WuXi Biologics Campus adjacent to the "Factory of the Future" biologics drug substance manufacturing facility which is scheduled for commercial manufacturing in 2021.